Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Akt3 inhibits adipogenesis and protects from diet-induced obesity via WNK1/SGK1 signaling
Liang Ding, Lifang Zhang, Sudipta Biswas, Rebecca C. Schugar, J. Mark Brown, Tatiana Byzova, Eugene Podrez
Liang Ding, Lifang Zhang, Sudipta Biswas, Rebecca C. Schugar, J. Mark Brown, Tatiana Byzova, Eugene Podrez
View: Text | PDF
Research Article Metabolism

Akt3 inhibits adipogenesis and protects from diet-induced obesity via WNK1/SGK1 signaling

  • Text
  • PDF
Abstract

Three Akt isoforms, encoded by 3 separate genes, are expressed in mammals. While the roles of Akt1 and Akt2 in metabolism are well established, it is not yet known whether Akt3 plays a role in metabolic diseases. We now report that Akt3 protects mice from high-fat diet–induced obesity by suppressing an alternative pathway of adipogenesis via with no lysine protein kinase-1 (WNK1) and serum/glucocorticoid-inducible kinase 1 (SGK1). We demonstrate that Akt3 specifically phosphorylates WNK1 at T58 and promotes its degradation via the ubiquitin-proteasome pathway. A lack of Akt3 in adipocytes increases the WNK1 protein level, leading to activation of SGK1. SGK1, in turn, promotes adipogenesis by phosphorylating and inhibiting transcription factor FOXO1 and, subsequently, activating the transcription of PPARγ in adipocytes. Akt3-deficient mice have an increased number of adipocytes and, when fed a high-fat diet, display increased weight gain, white adipose tissue expansion, and impaired glucose homeostasis. Pharmacological blockade of SGK1 in high-fat diet–fed Akt3-deficient mice suppressed adipogenesis, prevented excessive weight gain and adiposity, and ameliorated metabolic parameters. Thus, Akt3/WNK1/SGK1 represents a potentially novel signaling pathway controlling the development of obesity.

Authors

Liang Ding, Lifang Zhang, Sudipta Biswas, Rebecca C. Schugar, J. Mark Brown, Tatiana Byzova, Eugene Podrez

×

Figure 4

Akt3 regulates SGK1 activity via WNK1.

Options: View larger image (or click on image) Download as PowerPoint
Akt3 regulates SGK1 activity via WNK1.
(A) Western blot analysis of WNK1...
(A) Western blot analysis of WNK1 expression in Akt3–/– MEF and Akt3–/– adipocytes of female mice; WNK1 and Akt3 expression in 3T3-L1 cells treated with Akt3 siRNA or WNK1 siRNA; WNK1 and phospho-NDRG1/NDRG1 ratio (SGK1 activity) in human preadipocytes treated with Akt3-specific siRNA. n = 3. (B) Western blot analysis of WNK1, NDRG1, Phospho-NDRG1 expression in Akt3–/– MEF transfected with WNK1 siRNA for 24 hours. n = 4. (C) Adipogenesis assay using 3T3-L1 cells transfected with Akt3 siRNA or WNK1 siRNA, or cotransfected with Akt3/WNK1 siRNA for 24 hours. Scale bar: 100 μm. n = 5. (D) Comparable WNK1 mRNA expression in WT and Akt3–/– MEF using quantitative PCR; β-actin mRNA used as a loading control. n = 7. (E) Immunoprecipitation of WNK1 from WT and Akt3–/– MEF lysates after a 2-hour pulse-label with [35S] methionine. Experiment was repeated 3 times. n = 4. (F) Decreased phosphorylation of WNK1 (Thr58) in Akt3-deficient MEF. n = 4. (G) WNK1 expression in WT and Akt3–/– MEF treated with cycloheximide (10 μg/ml) for 6, 12, and 24 hours; β-actin used as a loading control. n = 3. (H) Immunoprecipitation of WNK1 from WT and Akt3–/– MEF lysates with treatment of MG132 (MG, 5 μM) for 20 hours, followed by SDS-PAGE and immunoblotting using anti-ubiquitin antibody and anti-WNK1 antibody. n = 4. (I) WNK1 expression in WT and Akt3–/– MEF treated with proteasome inhibitor MG132 (MG, 5 μM) or Bortezomib (Bor, 10 nM) for 24 hours; β-actin used as a loading control. n = 3. (J) Expression of WNK1, SGK1, NDRG1, and phosphorylation of NDRG1 in WT and Akt1–/– MEF cells. Scale bar: 100 μm. Data represent means ± SEM. *P < 0.05 by 2-tailed Student’s t test.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts